Menkes disease (#309400) is a rare neurodevelopmental disorder caused by mutations
in a copper-transport gene, ATPA7. Clinical symptoms include muscular hypotonia, statomotoric
retardation and seizures. Death occurs in most children before three years of age.
Treatment with copper histidine may improve long term prognosis if the injections
are started within the first days to weeks after birth. Measurement of serum copper
and coeruloplasmin shows insufficient sensitivity and specificity in newborns for
diagnosis of Menkes disease. Both the measurement of copper in cultured fibroblasts
and the molecular analysis of the ATP7A gene could take several weeks for a definitive
diagnosis. Another test for diagnosis of Menkes disease is the measurement of plasma
catecholamine levels. Because of a defect in the copper-dependent dopamine-β-hydroxylase
there are deficiencies in norepinephrine and dihydroxyphenylglycol (DHPG) and excess
of dopamine and. dihydroxyphenylacetic acid (DOPAC). Especially the ratio of DOPAC
to DHPG was proposed in the literature as a reliable method to diagnose Menkes disease.
Reference intervals for the described catecholamine levels for newborns have not been
published so far.
We present the catecholamine levels of an 11 month-old caucasian boy with the molecular
diagnosis of Menkes disease and reference intervals from 107 term and preterm infants
at the age of 1 to 18 weeks of life. The average value for DHPG was 1892 pg/ml, for
DOPAC 3218 pg/ml. The ratios of DOPAC to DHPG were 1.72 on average (range: 0.83–3.04).
The stated reference intervals are comparable with data from smaller series in the
literature.
Measurement of plasma catecholamines is a promising method for early diagnosis of
Menkes diesease in newborns. Following early therapeutic interventions with copper
injections can improve outcomes, depending on underlying mutations.